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a b s t r a c t
Bone is the most common site for metastasis in patients with solid tumours. Bisphosphonates are an
effective treatment for preventing skeletal related events and preserving quality of life in these patients.
Zoledronic acid (ZA) is the most potent osteoclast inhibitor and is licensed for the treatment of bone
metastases. Clodronate and pamidronate are also licensed for this indication.
In addition, ZA has been demonstrated to exhibit antitumour effect. Direct and indirect mechanisms
of anti-tumour effect have been postulated and at many times proven. Evidence exists that ZA
antitumour effect is mediated through inhibition of tumour cells proliferation, induction of apoptosis,
synergistic/additive to inhibitory effect of cytotoxic agents, inhibition of angiogenesis, decrease tumour
cells adhesion to bone, decrease tumour cells invasion and migration, disorganization of cell cytoskeleton
and activation of speciﬁc cellular antitumour immune response. There is also clinical evidence from
clinical trials that ZA improved long term survival outcome in cancer patients with and without bone
metastases. In this review we highlight the preclinical and clinical studies investigating the antitumour
effect of bisphosphonates with particular reference to ZA.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bisphosphonates are proven to be effective in preventing/delaying
skeletal-related events in patients with bone metastases and poten-
tially preserving functional independence and quality of life. This effect
is mediated by the inhibitory effect of bisphosphonates on osteoclasts.
Recently, it has been reported that bisphosphonates may have
anti-tumour effect as well.
There are two classes of bisphosphonates that differ with regard
to structure and mechanism of action [1]. The ﬁrst one includes
pyrophosphate-resembling bisphosphonates, such as clodronate and
etidronate, which are metabolically incorporated into nonhydrolyz-
able adenospine tri-phosphate (ATP) analogues that act as inhibitors
of ATP-dependent enzymes. The second class which is more recent
and potent includes nitrogen-containing bisphosphonates (N-BPs),
such as alendronate, pamidronate, risedronate, ibandronate and
zoledronic acid (ZA).
N-BPs inhibit a key enzyme, farnesyl diphosphonate (FPP)
synthase, in the biosynthetic mevalonate pathway. As a result, these
compounds interfere with a variety of cellular functions essential for
the bone-resorbing activity and survival of osteoclasts. Several
intermediates in this pathway (Fig. 1), including farnesyl pyropho-
sphate and geranylgeranyl pyrophosphate, are required for the post-
translational modiﬁcation (i.e., prenylation) of guanosine
triphosphate-binding proteins such as Ras, Rho, and Rac. These
signalling molecules are involved in the regulation of cell prolifera-
tion, cell survival, and cytoskeletal organization [2,3].
ZA is reported to be more potent inhibitor of farnesyl dipho-
sphate synthase than the other bisphosphonates risedronate, iban-
dronate, incadronate, alendronate, and pamidronate [4].
Preclinical ﬁndings provide insight into possible mechanisms of
action of bisphosphonates that may explain their ability to inhibit
tumour cells. This report reviews the preclinical and clinical data
investigating the anti-tumour effects of ZA.
1.1. Preclinical rationale for potential anticancer effects of ZA
Preclinical data indicate that possible anti-cancer mechanisms
of ZA (and other bisphosphonates) may include (Fig. 2):
 Inhibition of tumour cell proliferation and induction of
apoptosis.
 Augmentation of inhibitory effect of cytotoxic agents (additive
and synergistic effect).
 Inhibition of angiogenesis.
 Decrease in tumour cell adhesion to bone.
 Decrease in tumour cells invasion and migration and disorga-
nization of cell cytoskeleton.
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 Activation of γδ T cells.
 Effects on tumour macrophage inﬁltration.
Preclinical studies investigating these possible mechanisms of
action are presented below and summarized in Table 1.
1.1.1. Inhibition of tumour cell proliferation and induction of
apoptosis
ZA inhibits a key enzyme of the mevalonate pathway, farnesyl
diphosphonate synthase.
Inhibition of this enzyme prohibits formation of isoprenoids,
such as farnesyl diphosphate (FPP) and geranylgeranyl dipho-
sphate (GGPP), which are required for regular prenylation of small
GTPbinding proteins, like Rho and Ras (Fig. 1) [5].
There is signiﬁcant preclinical evidence to support the direct
antitumour effect of ZA. In a preclinical study, ZA strongly inhibited
in vitro proliferation, arrested cell cycle between S and G2/M
phases, and induced the apoptosis of human ﬁbrosarcoma cells
[6]. The same group of investigators reported inhibition of growth
of osteosarcoma cells at the primary and secondary sites in a
murine model [7].
In another study, Zwolak et al. showed that ZA can be released
from bone cement (formed with increasing concentrations of ZA, up
to 1 mg/1.5 cm3 of bone cement) and the proliferation assay showed
ZA to have signiﬁcant dose dependent cytotoxicity in cultures of
stromal giant cell tumour, multiple myeloma, and renal cell carci-
noma cells [8]. In a separate study, ZA showed direct antitumor
effects against four oral carcinoma cell lines at concentrations
ranging from 10 to 100 mM. ZA activated the potent pro-apoptotic
pathways caspase-3, -8 and -9 and induced cellular apoptosis and
increased the number of cells in apoptosis. Western blot analysis
showed that ZA increased cleaved anti-human poly(ADP-ribose)
polymerase expression and decreased Bcl-2 and Bid expression
[9]. In renal cancer cell lines (ACHN, A-498 and CAKI-2), a signiﬁcant
reduction in viable cells was seen for all three cell lines following
treatment with ZA (at concentrations of 6.25–100 mM), compared
with untreated controls. A concomitant increase in the apoptosis
signiﬁcant caspase-dependent M30 antigen was demonstrated.
This effect could be blocked by the pan-caspase inhibitor Z-VAD
[10]. Similar apoptotic effect of ZA (in concentrations of 5–40 mM)
Fig. 1. Flowchart showing the mevalonate pathway.
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was seen in dexamethasone resistant multiple myeloma (MM)
cells [11].
The preclinical evidence of antitumour effect is well documen-
ted for other solid tumour models as lung, breast and prostate
[12,13].
It seems that at least in the preclinical setting, there is substantial
evidence supporting the anti-proliferative effect of ZA mainly by
inducing apoptosis. This mechanism is amenable to be studied in
clinical setting. Although a 15min intravenous infusion of 4 mg ZA
achieves a maximum concentration 0.97 mM (Product Information:
RECLAST(R) IV injection, zoledronic acid IV injection. Novartis Pharma
Stein AG, Stein, Switzerland, 2008), some preclinical experiments in
mouse models with metastatic breast cancer to bone have demon-
strated in-vivo that alternative dosage regimens with ZA (daily and
weekly administration in divided doses) can cause decrease in tumour
burden in the bone (PMID: 17312309). Therefore daily or weekly
treatment regimens of ZA (in divided doses) may be amenable to
further investigation in clinical trials.
1.1.2. Augmentation of inhibitory effect of cytotoxic agents (additive
and synergistic effect)
Enhancing the cytotoxic effect of anti-cancer drugs on tumour
cells has always been an active area of research. In the clinical
setting, cancer patients on systemic anti-cancer therapy (chemo-
therapy or hormonal therapy) may receive ZA for reasons other
than its possible anti-tumour effect. It seems attractive to inves-
tigate potential additive/synergistic effect of ZA to chemotherapy
and/or hormonal therapy. The available literature conﬁrms this
effect in pre-clinical studies.
In one study, hormone-refractory prostate cancer cell lines (PC3
and DU145) were treated with increasing concentrations of ZA in
the absence or presence of docetaxel. After 72 h incubation, ZA at
concentration of 25 μM reduced the viable cell number to 68% and
98% for PC3 and DU145 cells respectively. Docetaxel, on the other
hand, at a concentration of 0.1 ng/ml, had no effect on the viability.
However, a combination of ZA and docetaxel reduced the cell number
to 60% and 81% respectively. ZA in the concentration range 12.0–
50 μM enhanced the antitumoral effects of docetaxel (0.01–1 ng/ml)
in an additive and/or synergistic manner for both cell lines [14].
These results were repeated by another group of investigators
using the same agents and cell lines [15]. Additive/synergistic
inhibitory effect of ZA is also documented with other chemother-
apy agents as paclitaxel, docetaxel, doxorubicin, etoposide, 5-ﬂuoro-
uracil, gemcitabine, and cisplatin [6,16,17].
The additive and/or synergistic effect of ZA may be dependent
on the sequence of treatment. Studies suggest that Sequential
treatment with chemotherapy followed by ZA elicit substantial
antitumor effects compared to the reverse sequence. Female MF1
nude mice were inoculated human breast cancer MDA-MB-436
cells. On day 7, the mice were injected weekly for 6 weeks with
saline, doxorubicin or ZA alone, combination of both, ZA followed
24 h later by doxorubicin, or doxorubicin followed 24 h later by ZA.
Treatment with doxorubicin followed by ZA almost completely
abolished tumour growth. Tumours from mice in this group had
signiﬁcantly more caspase-3-positive cells than tumours from
mice treated with saline, with ZA alone or with ZA followed by
doxorubicin. This increase in the number of caspase-3-positive
cells was mirrored by a decrease in the number of tumour cells
positive for the proliferation marker Ki-67. The authors concluded
that sequential treatment with doxorubicin followed by ZA elicited
substantial antitumor effect [18].
Synergism is not only limited to chemotherapy. There is evi-
dence that ZA can augment inhibitory effect of hormonal therapy.
Aromatase-expressing breast cancer cells were treated with letro-
zole (100 nM) and ZA(10 μM) either simultaneously or in sequence,
each for 24 h. Letrozole and ZA induce levels of apoptosis in breast
cancer cells in vitro that are signiﬁcantly greater compared with
Fig. 2. Possible mechanisms of anti-tumour effect of ZA.
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treatment with each drug alone. However, this potentially syner-
gistic relationship was drug-sequence dependent, occurring only
when cells were treated with letrozole, followed by ZA [19].
These studies suggest the additive and synergistic effect of
ZA with other anti-cancer agents. The exact mechanisms remain
unknown but down-regulation of anti-apoptotic genes has been
suggested [15]. Preclinical data showed increased anti-tumour efﬁ-
cacy if ZA is sequenced after chemotherapy compared to the opposite
sequence [20]. Based on this observation, most clinical trials inves-
tigating the role of ZA in the neo-adjuvant setting including
NEOZOTAC [21], ANZAC [22] and NeoAZURE [23] administered ZA
after chemotherapy. The adjuvant phase III AZURE study is also an
example where investigators used ZA after chemotherapy [24].
The sequence of administration may need to be addressed in
future clinical trials. One clinical investigational approach will be
to randomize patients in the neoadjuvant or metastatic setting to
different sequences of ZA and speciﬁc anti-cancer therapy. Pre-
treatment and post-treatment biopsies to study molecular changes
may help elucidate mechanisms of this additive/synergistic effect.
1.1.3. Inhibition of angiogenesis
Angiogenesis is a prerequisite for the progressive growth of solid
tumours and their metastasis [25]. In malignant tumours, the devel-
opment of new vessels is directed and regulated by a complex
network of endogenous pro-angiogenic factors, e.g. vascular endothe-
lial growth factor (VEGF) and basic ﬁbroblast growth factor (bFGF)
and by factors secreted by the tumour itself. Angiogenesis enables the
tumour to metastasize to various sites. Thus, inhibition of angiogen-
esis is a promising strategy in the treatment of malignant tumours.
Table 1
Summary of pre-clinical and early clinical [52,56,57] studies and publications describing various mechanisms of anti-tumour activity of nitrogen-containing
bisphosphonates.
Reference
number
Bisphosphosphonate(s) used Concentrations/
doses studied
Cell lines Results
Proliferation inhibition and apoptosis induction
[6] ZA Up to 10 mM Fibrosarcoma Inhibition, cell cycle arrest
[7] ZA 80 mg/kg Osteosarcoma Inhibition of growth
[8] ZA 1.55–4.48 mg/ml Giant cell tumour, myeloma,
renal cell carcinoma
Dose dependent cytotoxicity
[9] ZA 10–100 mM Oral carcinoma: 4 cell lines Induction of apoptosis (concentration dependent)
[10] ZA 6.25–100 mM Renal cell carcinoma: 3 cell lines Induction of apoptosis
[11] ZA Up to 20 mM Multiple myeloma Induction of apoptosis
[13] ZA Up to 10 mM Prostate and breast cancer Induction of apoptosis (concentration dependent)
[12] ZA 100 mM Non-small cell lung cancer
(NSCLC)
Cell cycle arrest, apoptosis induction
Additive and synergistic effect with cytotoxic agents
[14,15] ZA 12.5–50 mM Hormone resistant prostate
cancer
Additive and synergistic effect with docetaxel
5–30 mM
[16] ZA 10–100 mM Breast cancer Additive effect with paclitaxel
[17] ZA 100 mM NSCLC Additive effect with cisplatin
[6] ZA Up to 10 mM Fibrosarcoma Additive effect with various chemotherapy agents
[18] ZA 100 mg/kg Breast cancer Additive effect with doxorubicin (when used with or
after doxorubicin)
[19] ZA Up to 25 mM Breast cancer Synergistic effect with letrozole
Inhibition of angiogenesis
[12] ZA 10–100 mM Non-small cell lung cancer Reduction of VEGF secretion
[28] ZA Up to 200 mM Endothelial progenitor cells Reduction of viable cells
Decrease in tumour cell adhesion to bone
[37] ZA 100–1000 mM Multiple myeloma Decrease in bone marrow stromal cells, decreased
expression of adhesion molecules
[39] Ibandronate 1000 nM Breast and prostate cancer Inhibition of tumour cell binding to bone matrices
[40] Clodronate, pamidronate, olpedronate,
etidronate and ibandronate
1–100 mM
[38] Ibandronate 5 picoM
Pamidronate 0.1 mM
Clodronate 100 mM
Inhibition of tumour cell invasion and migration
[41,43] Reviews Breast and prostate cancer Inhibition of visceral metastasis
[42] ZA 1 mM
[44] ZA 0.5–5 mmg/
mouse
[45] Alendronate 30 mM Ovarian cancer Inhibition of cell migration
Activation of γδ T cells
[51] Alendronate, ibandronate and pamidronate 0.9–4 mM Multiple myeloma Reduced plasma cell survival due to activation of γδ T
cells
[52] ZA 4 mg every 3 weeks
(4 doses)
Metastatic bone disease Maturation of γδ T cells (in vivo)
[53] ZA 1 mM (with IL-2) Multiple myeloma Increase in number of γδ T cells
[55] ZA 1 mM (with IL-2) Small cell lung cancer and
ﬁbrosarcoma
Marked increase in sensitivity to lysis by γδ T cells
[54] ZA 3 mM Pancreatic cancer Increased cancer cell cytotoxicity by γδ T cells
[56] ZA Unknown Prostate cancer Activation and increase in number of γδ T cells
[57] ZA 4 mg (1 dose) Breast cancer Activation of γδ T cells
ZA¼zoledronic acid; mM¼micromolar; mg¼milligrams; picoM¼picomolar; γδ¼gamma delta.
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There is evidence that ZA inhibits differentiation of cultured
human peripheral blood mononuclear cells into endothelial
progenitor cells [26]. ZA inhibits proliferation of human endothelial
cells in vitro and reduces vessel sprouting in cultured aortic
rings and chicken egg chorioallantoic membrane assay [27]. This
study also provided the ﬁrst in-vivo evidence that ZA affects
angiogenesis occurring in non-mineralized tissue. However, ZA dose
of 100 μg/kg was required to achieve any signiﬁcant antiangiogenic
effect.
In one study, ZA at concentration of 10–100 μm induced dose
dependent reduction both of mRNA and protein expression of VEGF
in A549 NSCLC cells associated with parallel decrease in VEGF
secretion in the culture medium after 2 days of treatment [12].
In another study, the viability of human umbilicord vein
endothelial cells (HUVEC) and endothelial progenitor cells (EPC)
was signiﬁcantly reduced after incubation with bisphosphonates
compared with the non-treated control groups. The nitrogen-
containing bisphosphonates pamidronate and ZA had the greatest
impact on the cells, whereas the inhibitory effect of clodronate and
ibandronate on these cells was less distinct [28].
An in vivo studies show that ZA (20 μg/mouse) for 3 times a
week for3 consecutive weeks inhibited angiogenesis in Matrigel
plugs and inhibited the growth and neo-angiogenesis of CG5
xenografts in athymic nude mice [29]. Another in vivo study
documented that capillary densities were signiﬁcantly lower in
mice pre-treated with low dose (30 μg/kg) and high dose ZA
(100 μg/k) than in control mice in response to surgically induced
hypoxia. Ischaemic tissue from ZA pre-treated mice also showed
impaired mobilization of endothelial progenitor-like cells and
lower levels of the active form of MMP-9 and VEGF compared to
ischaemic tissue from control mice [30].
Another in-vivo supporting evidence that ZA uptake occurs
in non-mineralized tissue is provided by Stresing et al. ZA inhibi-
ted the revascularization of the prostate gland in testosterone-
stimulated castrated rats. It also induced intracellular accumulation
of isopentenyl pyrophosphate (IPP) in endothelial cells by blocking
the activity of the IPP-consuming enzyme FPPS. Thus, these results
indicated that N-BPs inhibited angiogenesis in a FPPS-dependent
manner [31].
The more potent antiangiogenic effect of nitrogen-containing
bisphosphonates compared to other bisphosphopnates in precli-
nical studies mirrors their superior efﬁcacy seen in clinical setting.
Recent in-vivo evidence showed that bone marrow endothelial
progenitor cells (BM EPCs) are affected after ZA administration. On
ﬂow cytometry, BM EPCs increased in response to acute parathyr-
oid hormone therapy but not when treatment was combined with
ZA. This observation provides indirect suggestion to uptake of ZA
by bone endothelial cells [32].
Accumulating reports have shown that cancer patients who
have received nitrogen-containing bisphosphonates such as ZA
occasionally manifest bisphosphonate-related osteonecrosis of the
jaw (BRONJ) following dental treatments including tooth extrac-
tion. Little is known about the pathogenesis of BRONJ to date. The
results of Kobayashi Y and his colleagues0 work showed that ZA
alters oral bacterial behaviours and delays wound healing of the
tooth extraction socket by inhibiting osteogenesis and angiogen-
esis. They conclude that these actions of ZA may be relevant to the
pathogenesis of ONJ [33]. This conclusion is supported by clinical
observation of higher incidence of ONJ in cancer patients treated
with ZA and anti-angiogenic agents [34,35].
The available data not only demonstrate the importance of
anti-angiogenic properties of ZA but also elucidates the potential
mechanism and molecular targets of this property.
Most of preclinical supporting evidence for the anti-angiogenic
properties of ZA comes from in vitro models and therefore further
evaluation in more animal models and humans is needed. One
challenge in clinical studies will be the need for higher concentra-
tions which seem to be needed to achieve anti-angiogenesis.
1.1.4. Decrease in tumour cell adhesion to bone
Recent studies have shown the importance of the microenviron-
ment in the pathophysiology of metastatic bone disease. Adhesive
interactions of tumour cells play an important role in up-regulating
the production of cytokines and growth factors by bone marrow
stromal cells, which consequently enhance tumour growth, bone
destruction, and tumour survival [36]. Multiple myeloma (MM)
tumour cells naturally home at bone marrow (BM) and provide
a model for studying the effect of bisphosphonates on behaviour of
tumour cells in this environment. Adhesion molecules facilitate
binding of MM cells to the BM stroma. There is rising laboratory
evidence that ZA decrease tumour cells adhesion to bone micro-
environment.
In one study, BM stromal cells, obtained from BM mononu-
cleated cells of eight patients with MM, were treated with increas-
ing concentrations of ZA, ranging from 104 to 105 M. After 3 days
of exposure ZA induced decrease in proliferation and increase in
apoptosis. Among the adhesion molecules, CD106, CD54, CD49d,
and CD40, which were strongly expressed at baseline, showed
a statistically signiﬁcant reduction compared with controls after
exposure to higher concentrations of ZA [37].
Bisphosphonate treatment in particular ZA and ibandronate
inhibit the binding of human breast and prostate cancer cells to
mineralized and unmineralized matrices [38–40].
Among possible anti-tumour mechanisms of ZA, the above
mechanism seems to be the one least studied in pre-clinical setting.
If this mechanism is conﬁrmed in clinical setting, it may demon-
strate an impact on development of bone metastases rather than
direct anti-tumour effect.
1.1.5. Decrease in tumour cell invasion and migration, and
disorganization of cell cytoskeleton
Tumour cell invasion is intrinsically linked to localized cell
surface proteolytic activity driven by matrix metalloproteinases
(MMPs), which facilitates cell detachment from matrix proteins,
thereby promoting cell migration. Nitrogen-containing bisphospho-
nates (NBPs) inhibit breast and prostate cancer cell invasion [41–45].
High concentrations of bisphosphonates inhibit the zinc-dependent
proteolytic activity of MMPs, whereas submicromolar concentra-
tions are sufﬁcient to inhibit tumour cell invasion [41]. Indeed,
alendronate and ZA inhibit ovarian and breast cancer cell migration,
by attenuating the geranylgeranylation of RhoA [42,44,45,37–39],
a key player in cell adhesion dynamics that drive cell motility. ZA
also inhibits the chemokine CXCL12-induced breast cancer cell
migration by decreasing the cell surface expression of CXCR4, the
receptor for CXCL-12 [42,37]. Therefore, the anti-invasive properties
of NBPs may be the result of the inhibition of distinct molecular
pathways that mediate cancer cell invasion in a coordinated fashion.
These compounds may eventually also inhibit MMP activity if high
local bisphosphonate concentrations are achieved in the tumour
microenvironment [46].
Denoyelle et al. studied the effect of ZA on the invasiveness
and morphology of MDA-MB-231 breast cancer cells. Treatment by
ZA for 18 h induced signiﬁcant inhibition of cell invasion starting
at concentration of 1 μM with higher concentrations (10–100 μM)
inducing more inhibition. One micromolar concentration of ZA was
chosen to study the effect on cell morphology. Untreated cells were
ﬂat and well spread. In contrast ZA induced dramatic morphological
changes characterized by a cell rounding and a disorganization of
actin cytoskeleton accompanied by a loss of stress ﬁbres formation
[42]. The investigators found that the observed inhibition of cell
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invasion by ZA was associated with decreased translocation of RhoA
from cytoplasm to the cell membrane.
Later work by different group of investigators demonstrated
that ZA inhibits HUVEC adhesion, survival, migration and actin
stress ﬁbre formation by interfering with protein prenylation
and has identiﬁed ERK1/2, JNK, Rock (RhoA target mediating actin
ﬁbre formation), FAK and PKB as kinases affected by ZA in a
prenylation-dependent manner [47].
It remains to be seen if these anti-invasion and anti-migration
effects of ZA combined with other anti-tumour effects can be
translated into managing early stage breast cancer to prevent
relapse and metastases.
1.1.6. Activation of γδ T cells
T cells bearing the T-cell receptor (TCR)- γδ represent a minor
subset of human peripheral T cells (1–10%). The physiologic function
of γδ T cells remains elusive, though some evidence suggests that γδ T
cells play a role in the “ﬁrst line of defence” against a broad spectrum
of invasive microorganisms such as mycobacteria. In addition, certain
hematopoietic tumour cells (e.g., Burkitt lymphoma cell line Daudi or
myeloma cell line RPMI 8226) are speciﬁcally recognized and lysed
by these T cells in vitro [48,49]. The recognition of ubiquitous
nonpeptide antigens by γδ T cells suggests a surveillance function
of these T cells for infected or transformed cells [50].
One of the early studies examining the stimulatory capacity of
bisphosphonates to γδ T cells was carried out by Kunzmann et al.
In their work alendronate, ibandronate, and pamidronate induced
signiﬁcant expansion of γδ T cells (Vγ9Vδ2 subset) in peripheral
blood mononuclear cell cultures of healthy donors. Pamidronate-
activated γδ T cells produced cytokines (i.e., interferon [IFN]-γ) and
exhibited speciﬁc cytotoxicity against lymphoma (Daudi) and
myeloma cell lines (RPMI 8226, U266). Pamidronate-treated BM
cultures of 24 patients with MM showed signiﬁcantly reduced
plasma cell survival compared with untreated cultures [51].
In another study examining the stimulatory capacity of ZA to γδ
T cells, nine patients with metastatic bone disease from breast and
prostate cancer were injected with ZA. Peripheral blood mono-
nuclear cells were collected before treatment, and 1 month and
3 months after the ﬁrst administration. The objective of this study
was to evaluate the in vivo effect of ZA on subsets of Vγ9Vδ2 cells.
The ﬁnal conclusion was that in vivo treatment with ZA induces
Vγ9Vδ2 cells to mature toward an IFNγ-producing effector pheno-
type, which may induce more effective antitumor responses [52].
Signiﬁcant numbers of reports followed and conﬁrmed the
stimulatory effect of ZA on γδ T cells. ZA induced proliferation of γδ
T cells from normal and MM patients. The cells produced IFN-γ and
exerted direct cell-to-cell antimyeloma activity. ZA plus IL-2
increased the absolute number of γδ T cells 298-768 fold after 14
days incubation [53].
Several studies showed that ZA not only induced marked
increase in sensitivity of tumour cells to lysis by γδ T cells [54,
55] but also increased the number of γδ T cell when IL-2 was co-
administered [56]. The activating effect of ZA on γδ T cells was also
observed in vivo in disease-free breast cancer patients after a
single-dose of ZA [57]. This observation may serve as a rationale
for clinical evaluation of ZA in the adjuvant setting. However,
recent evidence suggests that repeated treatment with ZA in vivo
reduces Vγ2Vδ2 T cell numbers and their responsiveness to
stimulation [58]. This may explain the inconsistent results seen
in large clinical trials investigating the role of ZA in adjuvant
setting (as discussed below).
1.1.7. Effects on tumour macrophage inﬁltration
Tumour cells interact with the surrounding microenvironment
to grow and develop. Macrophages are a major component of this
microenvironment, and are of particular interest as potential
therapeutic targets due to their central role in tumour progression.
It is accepted that tumour associated macrophages have an
important role in several stages of oncogenesis and tumour progres-
sion including tumour cell growth, angiogenesis, migration, inva-
sion, and metastasis [59]. Higher level of macrophage inﬁltration is
associated with poor prognosis in several tumour types [60]. There
is evidence that tumour macrophages play a role in regulating
angiogenesis and thus may promote tumour cells proliferation [61].
There is in vivo and in vitro evidence that tumour macrophages
uptake ZA. Exposure of J774 macrophages to 5 μM ZOL for 24 h
caused increased uptake of ZA. Higher doses and longer exposure
induced apoptotic cell death [62].
There is pre-clinical evidence that ZA is more potent macrophage
inhibitor than other bisphosphonates. J774A.1 cells were cultured in
a standard culture medium for 2-days. Bisphosphonates (alendro-
nate, pamidronate, etidronate, risedronate and ZA) were added
in the medium at concentration of 106–104 M during 3 days.
Etidronate did not cause signiﬁcant apoptosis or necrosis, at any
concentration. Alendronate and pamidronate caused apoptosis and
death only at very high concentration [104 M]. On the contrary,
apoptotic and necrotic cells were evidenced with risedronate or ZA
at lower concentrations [63].
Enhanced expression of Matrix Metalloprotinase-9 (MMP-9) in
macrophages is induced by interactionwith tumour cells. This plays a
major role in tumour cells invasion and metastasis. In vivo, treatment
with amino-biphosphonates was shown to impair tumour growth,
decrease MMP-9 expression and decrease the number of macro-
phages in tumour stroma [64].
ZA has been found to reverse the polarity of peritoneal and
tumour-associated macrophages from M2 to M1. This is a very
important ﬁnding, as M1 macrophages possess tumoricidal activ-
ity, supporting that TAMS are a potential immune target of ZOL
therapy [65].
The macrophage mediated anti-tumour effect of amino-biphos-
phonates is well established in pre-clinical studies. However, there
is lack of clinical studies conﬁrming this effect in cancer patients.
1.2. Early clinical (phase I/II) data regarding anticancer effects of
zoledronic acid
1.2.1. Direct cytotoxic effect of ZA
As discussed above, preclinical evidence suggests that bisphos-
phonates (with special reference to nitrogen containing bisphos-
phonates including ZA) possess inherent anti-tumour activity. These
data suggest that adding ZA to other systemic cancer therapies may
provide additional antitumor and anti-metastatic activity.
In the clinical setting, the results of large clinical trials inves-
tigating bisphosphonates less potent than ZA (clodronate and
pamidronate) were inconsistent [66,67]. Because of these potential
antitumor effects, ZA which is more potent than clodronate and
pamidronate has been investigated in early clinical studies in
cancer patients with and without metastases.
In one study, 40 patients with recurrent or metastatic advanced
cancer, without bone metastases, were randomized to receive ZA
or no treatment. Patients were followed up until bone metastases
were established. At 1 year, 60% of patients in ZA arm compared to
10% in the control group were bone metastases free (po0.0005).
At 18 months, the percentages were 20% and 5% (p¼0.0002) [68].
In a phase II trial, 120 women with clinical stage II–III breast
cancer planned for four cycles of neoadjuvant chemotherapy were
randomised to receive 4 mg ZA intravenously every 3 weeks or no
ZA for 1 year. The primary endpoint was the number of patients
with detectable disseminated tumour cells (DTCs) at 3 months.
At baseline, DTCs were detected in 43% of patients in the ZA group
and 48% of patients in the control group. At 3 months, 30% patients
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receiving ZA versus 47% of patients who did not receive ZA had
detectable DTCs (p¼0.054) [69]. The antitumour effect of ZA on
bone marrow DTC in women with early breast cancer was also
shown by other investigators [70,71].
1.2.2. Inhibition of angiogenesis
In an Italian study, 42 breast cancer patients with bone metastases
were treated with a single infusion of 4 mg ZA before anticancer
chemotherapy. The patients were prospectively evaluated for circulat-
ing levels of VEGF just before and at 1, 2, 7, and 21 days after ZA
infusion. Serum VEGF median levels were signiﬁcantly decreased at
each time point after treatment, but the major reductionwas recorded
21 days after the infusion. Twenty-ﬁve patients (59.5%) experienced a
reduction of at least 25% in the VEGF circulating levels. The analysis of
survival showed that patients with a reduction in VEGF circulating
levels had longer time to ﬁrst skeletal-related event (p¼0.0002), time
to bone progression disease (p¼0.0024), and time to performance
status worse (p¼0.0352) than those without the VEGF reduction. No
statistically signiﬁcant differences were recorded in terms of overall
survival and time to visceral progression [72]. This study conﬁrms that
ZA has an in vivo antiangiogenic property and that VEGFmodiﬁcations
may represent a surrogate marker to outcome.
These results were repeated by the same group in another 24
patients. Moreover, there was signiﬁcant correlation between
median VEGF and the bone resorption marker betaCTX [73].
Interestingly, in both studies [72,73] serum VEGF levels showed
sustained suppression after a single dose of ZA. This is in parallel
to the ﬁnding that repeated treatment with ZA in vivo reduces
Vγ2Vδ2 T cell numbers and their responsiveness to stimulation
[58]. These ﬁndings raise the question of the number of ZA doses
that should be considered optimal for future clinical trials.
Reduction in circulating VEGF appeared to be long lasting and
persisted as long as patients were receiving ZA [74]. In a study of 60
breast cancer patients with bone metastases, metronomic ZA was
more effective than the conventional regimen and generated sus-
tained reductions in circulating VEGF and bone resorption marker
levels, as well as stabilization of serum CA 15-3 levels [75,61]. It is
interesting that metronomic dose of ZA (1 mg weekly) also reduced
serum level of VEGF in cancer patients in other studies [74,75]. Other
early clinical studies showed different results. In a study with 18
breast cancer patients with bone metastases, serum VEGF level
showed a statistically signiﬁcant decrease 48 h after ZA infusion but
rose above the basal level at 7 days [76]. In another study of 30
patients with metastatic bone disease from breast and lung cancer
ZA acid did not exert signiﬁcant reduction of VEGF and bFGF
circulating levels 7 days after treatment [77]. These studies further
bring to question the optimal dose and frequency of ZA that should
be used in future clinical trials.
1.2.3. Activation of γδ T cells
A phase I study showed that administration of ZA (with IL-2) to
patients with metastatic cancer promoted effector maturation of
γδ T cells. Three patients who showed sustained robust peripheral
γδ T cell populations had decrease in their tumour marker levels,
with one patient achieving partial response and two achieving
stable disease. In contrast, seven other patients who failed to
sustain peripheral γδ T cells showed clinical deterioration [78].
In a Japanese study, peripheral blood mononuclear cells from
15 patients with advanced non-small cell lung cancer (NSCLC)
were stimulated with ZA (5 μM) and IL-2 (1000 IU/ml) for 14 days.
Many of these cells expanded to γδ T cells. Administration of these
ex vivo expanded γδ T cells to patients with recurrent or advanced
lung cancer was well tolerated. The number of peripheral γδ T cells
gradually increased. All patients remained alive during the study
period with a median overall survival of 589 (range 202–1505)
days, and median progression free survival of 126 (range 34–285)
days [79]. According to the Response Evaluation Criteria in Solid
Tumours (RECIST), there were no objective responses. Six patients
had stable disease, whereas the remaining six evaluable patients
experienced progressive disease 4 weeks after the sixth transfer.
Although all of these patients had Eastern Cooperative Group
(ECOG) performance status 0 or 1 with minimal co-morbidities,
such a long period of survival is very encouraging for recurrent or
advanced lung cancer. The reported median survival in this study
is about 1.5 times longer than that reported in large phase III lung
cancer trial.
Results from other studies were less promising. For example, in
a study of 12 patients with renal cell carcinoma, ZA induced only
modest increase in γδ T cell frequency but not to the magnitude
anticipated from preclinical models [80].
Recently, investigators have shed some light on possible reason
for the lack objective responses of solid tumours to γδ T cells
expansion therapy. Using similar expansion technique, Kunzmann
et al. treated 21 adults with advanced malignancies (renal cell
carcinoma [RCC], malignant melanoma, and acute myeloid leu-
kaemia). No objective responses were observed in both cohorts of
solid tumours (RCC and malignant melanoma), whereas two
patients with acute myeloid leukaemia (25%) achieved objective
tumour responses. Pharmacodynamic analyses showed signiﬁcant
in vivo activation (interferon-γ production) and expansion of γδ
T cells in all evaluable patients. High pretreatment serum VEGF
levels and an unexpected increase in VEGF induced ZA plus low-
dose interleukin-2 were correlated with the lack of a clinical
response. This study indicates that immunotherapy-induced VEGF
can limit clinical innate tumour immune responses, especially for
angiogenesis-dependent solid tumours. Adoptive immunotherapy
in this context is still at its infancy and further early clinical studies
may elucidate its potential role.
1.3. Phase III trials of zoledronic acid in early breast cancer
Based on early clinical data suggesting its anti-tumour effect,
ZA has been studied in multiple large randomized clinical trials in
early breast cancer.
In an Austrian study (ABCSG-12) [81], 1803 endocrine respon-
sive early breast cancer patients on adjuvant goserelin were
randomly assigned to receive, tamoxifen or anastrozole, with or
without ZA. The dose of ZA was 4 mg given intravenously every
6 months for 3 years. There was a 36% decrease in the risk of
disease progression (p¼0.01) in the ZA arms. This corresponded to
a 5 year disease free survival of 94% versus 90.8%, favouring ZA.
There were also fewer deaths in the ZA arms (16 versus 26, hazard
ratio 0.60, p¼0.11). Interestingly, patients on the ZA arms had
fewer events in all examined categories including loco regional
recurrence (10 versus 20), distant recurrence (29 versus 41), and
contra lateral breast cancer (6 versus 10) as compared to treatment
without ZA.
An integrated analysis [82] of two large randomized controlled
trials (Z-FAST and Zo-FAST) treating a total of 1667 patients with
early breast cancer was performed. The patients on these studies
were randomized to receive adjuvant hormonal therapy (letro-
zole), with either upfront ZA or delayed ZA (at time of decreased
bone mineral density). The analysis was aimed primarily to assess
the protective effect of ZA in prevention of bone density loss. One
of the secondary objectives of the analysis was time to disease
recurrence. The results showed that patients treated with upfront
ZA had signiﬁcantly less recurrences at 12 months as compared to
the patients who received delayed ZA (0.84% versus 1.9%, p¼0.04).
An updated analysis of the ZO-FAST study at 36 months showed
continued beneﬁt of upfront ZA in prolonging disease free survival
(41% relative risk reduction, p¼0.04) as compared to delayed ZA
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[83]. A more recent analysis at 60 months showed continued
beneﬁt of prolonged disease free survival (HR0.66, p¼0.0375) in
the upfront ZA group [84].
A third study (AZURE) [24] randomized 3360 patients with
early breast cancer to receive standard adjuvant therapy with or
without ZA. ZA was administered immediately after each cycle of
adjuvant chemotherapy in line with pre-clinical data supporting
this sequence as discussed above and was continued for a total of
5 years.
At a median follow up of 59 months, the investigators found no
signiﬁcant difference between the two arms in the primary end-
point which was disease free survival (77% in each group, p¼0.79).
Prospective subgroup analyses of the study showed that ZA
signiﬁcantly increased disease free survival (HR¼0.76, po0.05)
in women who were at least 5 years past menopause at study
entry (n¼1041). ZA also improved overall survival (HR¼0.71,
p¼0.017, n¼1101) in this patient population along with women
of unknown postmenopausal status but age greater than 60 years
[85]. Of note, about 45.8% of patients in this study were preme-
nopausal, 95% of whom received chemotherapy, and only 0.2% of
these patients received goserelin. This is in contrast to the pre-
menopausal patient cohort in the ABCSG-12 trial, who all received
goserelin.
Apparently the results of the AZURE study are in contradiction
to the ABCSG-12 results. However, some authorities have argued
that in both studies, disease free and overall survival was seen in
patients who were either rendered menopausal (with goserelin in
ABCSG-12 trial), or who achieved menopause naturally (as seen
in the subset analyses of the AZURE trial), suggesting a possible
relationship of a menopausal or low oestrogen state with the
clinical beneﬁt achieved from addition of ZA [86].
205 Patients in the AZURE study received neo-adjuvant treat-
ment including ZA. A retrospective analysis of pathologic response
in these patients [23] showed that the mean residual tumour size
in the ZA plus chemotherapy arm was signiﬁcantly less (15.5 mm)
as compared to 27.4 mm in the chemotherapy only arm. The
pathologic complete response rate was 11.7% in the ZA arm versus
6.9% in the chemotherapy only arm, but this was not statistically
signiﬁcant (p¼0.146).
Although the ABCSG-12 and AZURE studies have provided
provocative and interesting conclusions, the partly contradicting
results of these trials has delayed the incorporation of ZA in the
adjuvant treatment of women with early breast cancer.
A prospective study in postmenopausal patients is required to
validate and conﬁrm the results of the ABCSG-12 and AZURE trials.
This will also be an opportunity to study speciﬁc biomarkers that
likely explain anti-tumour mechanism of ZA. As discussed above,
anti-angiogenesis and anti-proliferative properties of ZA seem to
be the most relevant mechanisms from early preclinical and small
clinical studies.
Several other large randomized controlled trials are evaluating
the anti-tumour efﬁcacy of ZA in the adjuvant setting (Table 2).
Most of these studies have completed accrual and are awaiting
maturation of the data.
1.4. Trials showing lack of beneﬁt from zoledronic acid
Although the above mentioned trials have shown some clinical
beneﬁt from the use of ZA in solid tumours, results from other trials
do not show clear beneﬁt from use of ZA. In a recent Italian study
[87], patients with controlled stage IIIA/B NSCLC were randomized
to receive ZA or no treatment. Progression free survival (PFS), which
was the primary endpoint of this trial, was 9 months for ZA versus
11.3 months for control (statistically non-signiﬁcant difference). Rate
of development of bone metastases was also similar in both arms
(6.6% in ZA arm and 9% in control arm, no signiﬁcant difference).
In an open label randomized phase II study, 119 female patients
with resectable stage II/III breast cancer [88], patients were
randomised to either receive ZA or no ZA starting with ﬁrst cycle
of chemotherapy. At 61.9 months of follow up, there was no
difference between the two arms in terms of disease free survival
(secondary end-point) or overall survival (tertiary end-point). A
subset analysis did show beneﬁt of ZA in improving disease free
survival (Hazard ratio 0.361, 95% conﬁdence interval 0.148–0.880)
Table 2
A summary of ongoing large clinical trials evaluating the use of Zoledronic acid in different cancers.
Study
name
Patient population Study design and treatment Primary
endpoints
References
NATAN 654 BC patients Standard therapy þ/ EFS at 5 y ClinicaTrials.gov No.
NCT00512993
ZA (4 mg IV q1mo; q3mo; q6mo) German Breast Group
SUCCESS 3754 BC patients
(stages I, II, and IIIA)
FEC/DOC þ/ GEM, then endocrine therapy plus ZA
for 2 y or 5 y
DFS at 5 y The SUCCESS Study Group 2009
www.Success-studie.de
SWOG
0307
5400 BC patients
(stages I, II, and IIIA)
ZA (4 mg q1mo; q3mo); CLO (1600 mg/d);
IBN (50 mg/d)
DFS and OS up to
10 y
ClinicTrials.gov No. NCT00127205
Southwest Oncology Group
ZEUS 1498 PC patients
(high-risk, early)
Standard therapy þ/ ZA (4 mg IV q3mo) EFS at 4 y Register no. 66626762 〈http://
www.controlled-trials.com/〉
European Association of Urology
RADAR 1071 PC (stage T2b-4) ADT for 6 mo or 18 mo þ/ ZA (4 mg IV q3mo) PSA-RFS at 18 mo ClinicalTrials.gov No.
NCT00193856
Trans-Tasman Radiation Oncology
Group
STAMPEDE 3300 PC patients
(high risk)
ADT and (1) no additional therapy; (2) DOC (q3wk); (3) celecoxib (BID);
(4) ZA (q3wk; q4wk); (5) DOCþZOL; (6) celecoxibþZA
FFS and OS
(multiple phases)
ClinicalTrials.gov Identiﬁer,
NCT00268476
Medical Research Council
Study 2419 446 NSCLC patients
(stage IIIA or IIIB)
ZA (4 mg IV q1mo) TTP ClinicalTrials.gov Identiﬁer
NCT00172042
Novartis 2009
CALGB
90202
680 pts with met PrCa
on ADT
ZA 4 mg IV every month versus placebo PFS and OS ClinicalTrials.gov Identiﬁer:
NCT00079001
BC indicates breast cancer; IBN, ibandronate; IV, intravenous; q4wk, every 4 weeks; þ/ , with or without; DFS, disease-free survival; FEC, combined 5-ﬂurouracil,
epirubicin, and cyclophosphamide; DOC, docetaxel; ZA, zoledronic acid; EFS, event-free survival; q1mo, monthly; q3mo, every 3 months; GEM, gemcitabine; OS, overall
survival; CLO, clodronate; PC, prostate cancer; ADT, androgen-deprivation therapy; PSA-RFS, prostate-speciﬁc antigen recurrence-free survival; BID, twice daily; FFS, failure
free survival; NSCLC, non-small cell lung cancer; TTP, time to progression.
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and overall survival (Hazard ratio 0.375, 95% conﬁdence interval
0.143–0.985) in patients whose tumours were oestrogen receptor
negative as opposed to oestrogen receptor positive, however the
study was not powered for this comparison. The authors suggest
that in oestrogen receptor negative breast cancer, ZA may have a
direct anti-tumour effect which may not be dependent on a low
oestrogen environment. The sample size in these two clinical
studies was too small to address the question of effect of ZA on
disease relapse in early cancer setting.
1.5. Other bone modifying agents in oncology
In addition to ZA and other bisphosphonates, there is a host of
other bone modifying agents in different phases of development.
These include (but are not limited to) Denosumab (a RANK-ligand
antibody), 223RaCl2 or Alpharadin (an alpha particle emitting agent),
and antibodies to sclerostin (which is an inhibitor of osteoblastogen-
esis) [89]. The detailed mechanisms of action of these agents and
whether they have anti-tumour effects are beyond the scope of this
review.
2. Conclusion
ZA has become an important component in treatment of cancer
patients. Apart from its role in bone preservation and reduction of
skeletal related events, there is preclinical and also clinical evidence
suggesting a direct anti-cancer effect of ZA. Several mechanisms of
action for this anti-tumour effect have been studied. The most
profound clinical evidence of this effect comes from a number of
large adjuvant breast cancer studies, although the results have not
been consistently in favour of antitumour effect of ZA. Other adjuvant
studies incorporating ZA are currently underway and those results
are awaited.
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